SLDB: solidbio.com Growth-Adjusted P/E Ratio
Solid Biosciences Inc. (SLDB) develops unique treatments for muscle pathologies, securing long-term revenue through patent protection. The PEG ratio confirms the asset's market value, with the indicator currently at 0.00. Pipeline growth is supported by a strong team of geneticists, while strategic alliances with clinics and M&A deals enhance the company's scientific potential.
Metric breakdowns and analytics for Solid Biosciences Inc. (SLDB)
- price and consensus price forecast:
- market capitalization information:
- business book valuation details:
- business debt structure and liquidity details:
- earnings and valuation multiples information:
SLDB - Net Profit|Expected Net Profit Solid Biosciences Inc.|SLDB - Price to Earnings Ratio|Price to Future Earnings Ratio Solid Corp|SLDB - PEG Multiple|Enterprise Value to EBITDA Ratio Solid Bio|SLDB - Operating profit EBITDA|Net earnings per one share for the last twelve months Solid Biosciences|SLDB - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months solidbio.com|SLDB - Net earnings per share growth this year|Expected earnings per share trend next year Solid Biosciences Inc.
Fundamental company analysis:SLDB, Solid Biosciences Inc
For Solid Biosciences Inc. (SLDB), whose valuation is based on confidence in the safety of gene therapy, the ratio of company value to growth rates on GURU.Markets serves as an indicator of fundamental potential. This metric compares the current P/E with earnings dynamics: a value below one signals that the asset is undervalued, allowing investors to objectively assess the market value of promising developments relative to their scaling rates.
Competing companies
Growth-Adjusted Market Cap to Net Income Tempus AI, Inc|PEG Multiple QGEN (Qiagen Group)|IONS: Growth-Adjusted P/E Ratio|RGEN: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio RNA (aviditybiosciences.com)|CRSP: PEG Multiple|WGS (GeneDx Holdings) - Price/Earnings to Growth Ratio|RARE (Ultragenyx Pharma) - PEG Multiple|Beam Tx (BEAM) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Sarepta Therapeutics, Inc. (SRPT)|TWST - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio 10x Genomics TXG|Growth-Adjusted Market Cap to Net Income Intellia Therapeutics Inc (NTLA)|Stoke - PEG Multiple|BioLife (BLFS) - Price/Earnings to Growth Multiple|WVE: PEG Multiple|MAZE - Growth-Adjusted Market Cap to Net Income|SION (Sionna Therapeutics) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Prime Medicine Inc PRME|Price/Earnings to Growth Ratio Taysha (TSHA)|uniQure Pharma - Growth-Adjusted P/E Ratio|PEG Multiple MGTX (MeiraGTx Holdings plc)|RGNX - Price/Earnings to Growth Multiple|Ocugen - PEG Multiple|Price to Earnings Adjusted for Growth Rate Pacific Biosciences of California, Inc.|Benitec (BNTC) - Price/Earnings to Growth Ratio|DSGN - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple RCKT|FDMT: Growth-Adjusted Payback Ratio|PEG Multiple LXEO|Growth-Adjusted Market Cap to Net Income korrobio.com|Price/Earnings to Growth Ratio Editas EDIT|SLN: Growth-Adjusted P/E Ratio|ProQR Therapeutics NV - PEG Multiple|Codexis, Inc. (CDXS) - Price/Earnings to Growth Multiple|SGMO (Sangamo Therapeutics, Inc.) - Price/Earnings to Growth Multiple|NAUT - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Metagenomi, Inc|Precision BioSciences Inc. (DTIL) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Generation Bio Co. (GBIO)|Price/Earnings to Growth Ratio BOLD (boundlessbio.com)|PEG Multiple XCUR (Exicure)|IMNN: Growth-Adjusted P/E Ratio|RXi Pharmaceuticals - PEG Multiple|MBIO: Price/Earnings to Growth Ratio|RNAZ: PEG Multiple|Growth-Adjusted P/E Ratio BNGO|Price/Earnings to Growth Ratio Applied DNA Sciences, Inc.|Growth-Adjusted P/E Ratio BLUE (bluebird bio Inc.)|PEG Multiple IPA|PEG Multiple Omega Therapeutics Corp (OMGA)|Price/Earnings to Growth Ratio Singular Genomics Systems OMIC|Growth-Adjusted Market Cap to Net Income regulusrx.com (RGLS)|SYRS - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Telesis Bio Inc.|TRACON (TCON) - Price/Earnings to Growth Ratio|UBX (Unity Biotechnology, Inc) - Price/Earnings to Growth Ratio
